Article Details
Retrieved on: 2021-08-05 20:03:45
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
$60 million milestone from Roche for prasinezumab received in 2Q 2021; $80 million milestone from Bristol Myers Squibb for PRX005 expected in 3Q ...
Article found on: www.globenewswire.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here